Studies done by Yanazume et al., 2003, showed that agonist-induced cardiac hypertrophy accentuates p300 transcriptional activity and that this agonist-mediated cardiac hypertrophy is reversed by the blocking of p300-HAT activity [8]. The gene discussed is EP300; the disease is cardiac hypertrophy.